- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- Dementia in the News
- Media Room
A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil
What is the purpose of this study?
The purpose of this clinical trial is to evaluate the efficacy and safety of PF-0521377 (SAM-760), a drug that has the potential to improve cognition and decrease some behavioral symptoms associated with Alzheimer's disease.
Who is eligible?
We are looking for participants who:
-- have a diagnosis of Alzheimer's disease
-- are ages 60 or older
-- have a reliable caregiver or family member who is able to accompany them to study visits
-- are in stable medical condition
-- are on stable doses of Aricept (donepezil)
-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)
Please see the attached study description for more information.
|Pfizer Web blurb.doc||26 KB|